Timothy Purwin

TitleInstructor
InstitutionThomas Jefferson University
DepartmentCancer Biology
Address233 S. 10th Street
Philadelphia PA 19107
Phone215-503-8843
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Chua V, Lopez-Anton M, Baqai U, Purwin TJ, Haj JI, Waltrich FJ, Trachtenberg I, Luo K, Tudi R, Jeon A, Han A, Chervoneva I, Davies MA, Aguirre-Ghiso JA, Sato T, Aplin AE. Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress. Sci Signal. 2024 Jun 11; 17(840):eadn8376. PMID: 38861613.
      Citations:    
    2. Kadamb R, Anton ML, Purwin TJ, Chua V, Seeneevassen L, Teh J, Angela Nieto M, Sato T, Terai M, Roman SR, De Koning L, Zheng D, Aplin AE, Aguirre-Ghiso J. Lineage commitment pathways epigenetically oppose oncogenic Gaq/11-YAP signaling in dormant disseminated uveal melanoma. bioRxiv. 2024 Mar 08. PMID: 38496663.
      Citations:    
    3. Baqai U, Kurimchak AM, Trachtenberg I, Purwin TJ, Haj JI, Han A, Luo K, Pachon NF, Jeon A, Chua V, Davies MA, Gutkind JS, Benovic JL, Duncan JS, Aplin AE. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma. J Biol Chem. 2023 Nov 01; 105418. PMID: 37923138.
      Citations:    
    4. Rosenbaum SR, Caksa S, Stefanski CD, Trachtenberg IV, Wilson HP, Wilski NA, Ott CA, Purwin TJ, Haj JI, Pomante D, Kotas D, Chervoneva I, Capparelli C, Aplin AE. SOX10 loss sensitizes melanoma cells to cytokine-mediated inflammatory cell death. Mol Cancer Res. 2023 Oct 17. PMID: 37847239.
      Citations:    
    5. Purwin TJ, Caksa S, Sacan A, Capparelli C, Aplin AE. Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas. iScience. 2023 Sep 15; 26(9):107472. PMID: 37636077.
      Citations:    
    6. Han A, Mukha D, Chua V, Purwin TJ, Tiago M, Modasia B, Baqai U, Aumiller JL, Bechtel N, Hunter E, Danielson M, Terai M, Wedegaertner PB, Sato T, Landreville S, Davies MA, Kurtenbach S, Harbour JW, Schug ZT, Aplin AE. Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth. Cancers (Basel). 2023 Jun 30; 15(13). PMID: 37444561.
      Citations:    
    7. Cai W, Nguyen MQ, Wilski NA, Purwin TJ, Vernon M, Tiago M, Aplin AE. A Genome-wide screen identifies PDPK1 as a target to enhance the efficacy of MEK1/2 inhibitors in NRAS mutant melanoma. Cancer Res. 2022 Jun 03. PMID: 35657206.
      Citations:    
    8. Baqai U, Purwin TJ, Bechtel N, Chua V, Han A, Hartsough EJ, Kuznetsoff JN, Harbour JW, Aplin AE. Multi-omics profiling shows BAP1 loss is associated with upregulated cell adhesion molecules in uveal melanoma. Mol Cancer Res. 2022 Apr 15. PMID: 35426938.
      Citations:    
    9. Capparelli C, Purwin TJ, Glasheen M, Caksa S, Tiago M, Wilski N, Pomante D, Rosenbaum S, Nguyen MQ, Cai W, Franco-Barraza J, Zheng R, Kumar G, Chervoneva I, Shimada A, Rebecca VW, Snook AE, Hookim K, Xu X, Cukierman E, Herlyn M, Aplin AE. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma. Nat Commun. 2022 03 16; 13(1):1381. PMID: 35296667.
      Citations:    
    10. Han A, Chua V, Baqai U, Purwin TJ, Bechtel N, Hunter E, Tiago M, Seifert E, Speicher DW, Schug ZT, Harbour JW, Aplin AE. Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma. Oncogene. 2022 02; 41(8):1129-1139. PMID: 35046531.
      Citations:    
    11. Rosenbaum SR, Tiago M, Caksa S, Capparelli C, Purwin TJ, Kumar G, Glasheen M, Pomante D, Kotas D, Chervoneva I, Aplin AE. SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects. Cell Rep. 2021 12 07; 37(10):110085. PMID: 34879275.
      Citations:    
    12. Chua V, Han A, Bechtel N, Purwin TJ, Hunter E, Liao C, Harbour JW, Aplin AE. The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma. Pigment Cell Melanoma Res. 2021 Aug 04. PMID: 34347929.
      Citations:    
    13. Han A, Purwin TJ, Bechtel N, Liao C, Chua V, Seifert E, Sato T, Schug ZT, Speicher DW, Harbour JW, Aplin AE. Correction to: BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors. Oncogene. 2021 Mar; 40(9):1753. PMID: 33510355.
      Citations:    
    14. Han A, Purwin TJ, Aplin AE. Roles of the BAP1 tumor suppressor in cell metabolism. Cancer Res. 2021 Jan 14. PMID: 33446574.
      Citations:    
    15. Han A, Purwin TJ, Bechtel N, Liao C, Chua V, Seifert E, Sato T, Schug ZT, Speicher DW, William Harbour J, Aplin AE. BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors. Oncogene. 2020 Nov 18. PMID: 33208912.
      Citations:    
    16. Teh JL, Purwin TJ, Han A, Chua V, Patel P, Baqai U, Liao C, Bechtel N, Sato T, Davies MA, Aguirre-Ghiso JA, Aplin AE. Metabolic adaptations to MEK and CDK4/6 co-targeting in uveal melanoma. Mol Cancer Ther. 2020 May 19. PMID: 32430489.
      Citations:    
    17. Nguyen MQ, Teh JLF, Purwin TJ, Chervoneva I, Davies MA, Nathanson KL, Cheng PF, Levesque MP, Dummer R, Aplin AE. Targeting PHGDH upregulation reduces glutathione levels and re-sensitizes resistant NRAS mutant melanoma to MEK inhibition. J Invest Dermatol. 2020 May 07. PMID: 32389536.
      Citations:    
    18. Rosenbaum SR, Knecht M, Mollaee M, Zhong Z, Erkes DA, McCue PA, Chervoneva I, Berger AC, Lo JA, Fisher DE, Gershenwald JE, Davies MA, Purwin TJ, Aplin AE. FOXD3 Regulates VISTA Expression in Melanoma. Cell Rep. 2020 Jan 14; 30(2):510-524.e6. PMID: 31940493.
      Citations:    
    19. Tiago M, Capparelli C, Erkes DA, Purwin TJ, Heilman SA, Berger AC, Davies MA, Aplin AE. Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma. Br J Cancer. 2020 Jan 14. PMID: 31932756.
      Citations:    
    20. Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, Berger AC, Hartsough EJ, Rodeck U, Alnemri ES, Aplin AE. Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov. 2019 Dec 03. PMID: 31796433.
      Citations:    
    21. Wilski NA, Del Casale C, Purwin TJ, Aplin AE, Snyder CM. Murine cytomegalovirus infection of melanoma lesions delays tumor growth by recruiting and re-polarizing monocytic phagocytes in the tumor. J Virol. 2019 Aug 02. PMID: 31375579.
      Citations:    
    22. Sanchez IM, Purwin TJ, Chervoneva I, Erkes DA, Nguyen MQ, Davies MA, Nathanson KL, Kemper K, Peeper DS, Aplin AE. In vivo ERK1/2 reporter predictively models response and resistance to combined BRAF and MEK inhibitors in melanoma. Mol Cancer Ther. 2019 Jul 03. PMID: 31270153.
      Citations:    
    23. Erkes DA, Field CO, Capparelli C, Tiago M, Purwin TJ, Chervoneva I, Berger AC, Hartsough EJ, Villanueva J, Aplin AE. The next generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner. Pigment Cell Melanoma Res. 2019 May 07. PMID: 31063649.
      Citations:    
    24. Hartsough EJ, Weiss MB, Heilman SA, Purwin TJ, Kugel CH, Rosenbaum SR, Erkes DA, Tiago M, HooKim K, Chervoneva I, Aplin AE. CADM1 is a TWIST1-regulated suppressor of invasion and survival. Cell Death Dis. 2019 Mar 25; 10(4):281. PMID: 30911007.
      Citations:    
    25. Chua V, Orloff M, Teh JL, Sugase T, Liao C, Purwin TJ, Lam BQ, Terai M, Ambrosini G, Carvajal RD, Schwartz G, Sato T, Aplin AE. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. EMBO Mol Med. 2019 Feb; 11(2). PMID: 30610113.
      Citations:    
    26. Lapadula D, Farias E, Randolph CE, Purwin T, McGrath D, Charpentier T, Zhang L, Wu S, Terai M, Sato T, Tall GG, Zhou N, Wedegaertner P, Aplin AE, Aguirre-Ghiso J, Benovic JL. Effects of Oncogenic Gaq and Ga11 Inhibition by FR900359 in Uveal Melanoma. Mol Cancer Res. 2018 Dec 19. PMID: 30567972.
      Citations:    
    27. Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. Cancer Discov. 2018 Dec; 8(12):1654. PMID: 30510016.
      Citations:    
    28. Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, Davies MA, Gershenwald JE, Krepler C, Aplin AE. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res. 2018 Oct 01; 78(19):5680-5693. PMID: 30115691.
      Citations:    
    29. Han S, Ren Y, He W, Liu H, Zhi Z, Zhu X, Yang T, Rong Y, Ma B, Purwin TJ, Ouyang Z, Li C, Wang X, Wang X, Yang H, Zheng Y, Aplin AE, Liu J, Shao Y. Publisher Correction: ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma. Nat Commun. 2018 Apr 06; 9(1):1404. PMID: 29626208.
      Citations:    
    30. Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. In vivo E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms. Cancer Discov. 2018 Mar 01. PMID: 29496664.
      Citations:    
    31. Han S, Ren Y, He W, Liu H, Zhi Z, Zhu X, Yang T, Rong Y, Ma B, Purwin TJ, Ouyang Z, Li C, Wang X, Wang X, Yang H, Zheng Y, Aplin AE, Liu J, Shao Y. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma. Nat Commun. 2018 01 02; 9(1):28. PMID: 29295999.
      Citations:    
    32. Hartsough EJ, Kugel CH, Vido MJ, Berger AC, Purwin TJ, Goldberg A, Davies MA, Schiewer MJ, Knudsen KE, Bollag G, Aplin AE. Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo. Mol Cancer Ther. 2018 Jan; 17(1):84-95. PMID: 29133617.
      Citations:    
    33. Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, Davies MA, Sato T, Aplin AE. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. Mol Cancer Ther. 2017 Mar; 16(3):516-528. PMID: 28138035.
      Citations:    
    34. Teh JL, Purwin TJ, Greenawalt EJ, Chervoneva I, Goldberg A, Davies MA, Aplin AE. An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma. Cancer Res. 2016 Sep 15; 76(18):5455-66. PMID: 27488531.
      Citations:    
    35. Vu HL, Rosenbaum S, Capparelli C, Purwin TJ, Davies MA, Berger AC, Aplin AE. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma. J Invest Dermatol. 2016 Feb; 136(2):453-63. PMID: 26967478.
      Citations:    
    36. Raman P, Purwin T, Pestell R, Tozeren A. FXYD5 is a Marker for Poor Prognosis and a Potential Driver for Metastasis in Ovarian Carcinomas. Cancer Inform. 2015; 14:113-9. PMID: 26494976.
      Citations:    
    37. Vu HL, Rosenbaum S, Purwin TJ, Davies MA, Aplin AE. RAC1 P29S regulates PD-L1 expression in melanoma. Pigment Cell Melanoma Res. 2015 Sep; 28(5):590-8. PMID: 26176707.
      Citations:    
    Purwin's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (59)
    Explore
    _
    Co-Authors (28)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _